Pathogenesis of chronic viral hepatitis: Differential roles of T cells and NK cells

Nature Medicine

Volumn 19, Issue 7, 2013, Pages 859-868

  Rehermann, Barbara ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE PROTEIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; HEPATITIS B SURFACE ANTIGEN; HLA A3 ANTIGEN; HLA B57 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL KILLER CELL RECEPTOR; NEUTRALIZING ANTIBODY; STAT1 PROTEIN; STAT4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADAPTIVE IMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; CROSS PRESENTATION; DISEASE COURSE; EFFECTOR CELL; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOGLOBULIN DEFICIENCY; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; KUPFFER CELL; LIVER CANCER; LIVER CIRRHOSIS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MACROPHAGE; MONONUCLEAR CELL; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STELLATE CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VERTICAL TRANSMISSION; VIRAL CLEARANCE; VIRUS HEPATITIS; VIRUS PATHOGENESIS; VIRUS TRANSMISSION;

ANIMALS; DISEASE PROGRESSION; HEPATITIS, CHRONIC; HEPATITIS, VIRAL, HUMAN; HUMANS; KILLER CELLS, NATURAL; MODELS, BIOLOGICAL; T-LYMPHOCYTES;

EID: 84880276248     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3251     Document Type: Review

References (165)

1. Guidotti, L.G. & Chisari, F.V. Immunobiology and pathogenesis of viral hepatitis. Annu. Rev. Pathol. 1, 23-61 (2006).
2. Rehermann, B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J. Clin. Invest. 119, 1745-1754 (2009).
3. Rehermann, B. & Nascimbeni, M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5, 215-229 (2005).
4. Thimme, R. et al. CD8+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J. Virol. 77, 68-76 (2003).
5. Shoukry, N.H. et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J. Exp. Med. 197, 1645-1655 (2003).
6. Boni, C. et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J. Virol. 81, 4215-4225 (2007).
7. Schurich, A. et al. Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-prone CD8 T cells in persistent hepatitis B virus infection. Hepatology 53, 1494-1503 (2011).
8. Penna, A. et al. Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology 45, 588-601 (2007).
9. Wedemeyer, H. et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J. Immunol. 169, 3447-3458 (2002).
10. Radziewicz, H. et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J. Virol. 81, 2545-2553 (2007).
11. McMahan, R.H. et al. Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J. Clin. Invest. 120, 4546-4557 (2010).
12. Bertoletti, A. et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 369, 407-410 (1994).
13. Rehermann, B., Pasquinelli, C., Mosier, S.M. & Chisari, F.V. Hepatitis B virus (HBV) sequence variation of cytotoxic T lymphocyte epitopes is not common in patients with chronic HBV infection. J. Clin. Invest. 96, 1527-1534 (1995).
14. Chang, K.M. et al. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J. Clin. Invest. 100, 2376-2385 (1997).
15. Timm, J. et al. Human leukocyte antigen-associated sequence polymorphisms in hepatitis C virus reveal reproducible immune responses and constraints on viral evolution. Hepatology 46, 339-349 (2007).
16. Wölfl, M. et al. Hepatitis C virus immune escape via exploitation of a hole in the T cell repertoire. J. Immunol. 181, 6435-6446 (2008).
17. Maini, M.K. et al. Direct ex vivo analysis of hepatitis B virus-specific CD8+ T cells associated with the control of infection. Gastroenterology 117, 1386-1396 (1999).
18. Lechner, F. et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 191, 1499-1512 (2000).
19. Rehermann, B., Ferrari, C., Pasquinelli, C. & Chisari, F.V. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat. Med. 2, 1104-1108 (1996).
20. Grakoui, A. et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 302, 659-662 (2003).
21. Dazert, E. et al. Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response. J. Clin. Invest. 119, 376-386 (2009).
22. Kim, A.Y. et al. Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes. Gastroenterology 140, 686-696.e1 (2011).
23. Fitzmaurice, K. et al. Molecular footprints reveal the impact of the protective HLA-Ac03 allele in hepatitis C virus infection. Gut 60, 1563-1571 (2011).
24. Semmo, N. et al. Maintenance of HCV-specific T-cell responses in antibody-deficient patients a decade after early therapy. Blood 107, 4570-4571 (2006).
25. Takaki, A. et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat. Med. 6, 578-582 (2000).
26. von Hahn, T. et al. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 132, 667-678 (2007).
27. Stoop, J.N. et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 41, 771-778 (2005).
28. Xu, D. et al. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J. Immunol. 177, 739-747 (2006).
29. Sugimoto, K. et al. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology 38, 1437-1448 (2003).
30. Das, A. et al. Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J. Exp. Med. 205, 2111-2124 (2008).
31. Dunn, C. et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J. Exp. Med. 204, 667-680 (2007).
32. Radziewicz, H. et al. Transient CD86 expression on hepatitis C virus-specific CD8+ T cells in acute infection is linked to sufficient IL-2 signaling. J. Immunol. 184, 2410-2422 (2010).
33. Das, A. et al. IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. J. Immunol. 189, 3925-3935 (2012).
34. Accapezzato, D. et al. Hepatic expansion of a virus-specific regulatory CD8+ T cell population in chronic hepatitis C virus infection. J. Clin. Invest. 113, 963-972 (2004).
35. Alatrakchi, N. et al. Hepatitis C virus (HCV)-specific CD8+ cells produce transforming growth factor ß that can suppress HCV-specific T-cell responses. J. Virol. 81, 5882-5892 (2007).
36. Neumann-Haefelin, C. et al. Human leukocyte antigen B27 selects for rare escape mutations that significantly impair hepatitis C virus replication and require compensatory mutations. Hepatology 54, 1157-1166 (2011).
37. Bucks, C.M., Norton, J.A., Boesteanu, A.C., Mueller, Y.M. & Katsikis, P.D. Chronic antigen stimulation alone is sufficient to drive CD8+ T cell exhaustion. J. Immunol. 182, 6697-6708 (2009).
38. Mueller, S.N. & Ahmed, R. High antigen levels are the cause of T cell exhaustion during chronic viral infection. Proc. Natl. Acad. Sci. USA 106, 8623-8628 (2009).
39. Rutebemberwa, A. et al. High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection. J. Immunol. 181, 8215-8225 (2008).
40. Jin, Y., Shih, W.K. & Berkower, I. Human T cell response to the surface antigen of hepatitis B virus (HBsAg). Endosomal and nonendosomal processing pathways are accessible to both endogenous and exogenous antigen. J. Exp. Med. 168, 293-306 (1988).
41. Boni, C. et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 143, 963-973 e9 (2012).
42. Bengsch, B. et al. Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog. 6, e1000947 (2010).
43. Nakamoto, N. et al. Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog. 5, e1000313 (2009).
44. Barber, D.L. et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682-687 (2006).
45. Golden-Mason, L. et al. Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J. Virol. 83, 9122-9130 (2009).
46. Raziorrouh, B. et al. The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+ T-cell function. Hepatology 52, 1934-1947 (2010).
47. Schlaphoff, V. et al. Dual function of the NK cell receptor 2B4 (CD244) in the regulation of HCV-specific CD8+ T cells. PLoS Pathog. 7, e1002045 (2011).
48. Blackburn, S.D. et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10, 29-37 (2009).
49. Mühlbauer, M. et al. PD-L1 is induced in hepatocytes by viral infection and by interferon-a and - and mediates T cell apoptosis. J. Hepatol. 45, 520-528 (2006).
50. Iwai, Y., Terawaki, S., Ikegawa, M., Okazaki, T. & Honjo, T. PD-1 inhibits antiviral immunity at the effector phase in the liver. J. Exp. Med. 198, 39-50 (2003).
51. Chen, C.H. et al. In vivo immune modulatory activity of hepatic stellate cells in mice. Hepatology 44, 1171-1181 (2006).
52. Isogawa, M., Furuichi, Y. & Chisari, F.V. Oscillating CD8+ T cell effector functions after antigen recognition in the liver. Immunity 23, 53-63 (2005).
53. Cao, D. et al. Intrahepatic expression of programmed death-1 and its ligands in patients with HBV-related acute-on-chronic liver failure. Inflammation 36, 110-120 (2013).
54. Wherry, E.J. T cell exhaustion. Nat. Immunol. 12, 492-499 (2011).
55. Grayson, J.M., Weant, A.E., Holbrook, B.C. & Hildeman, D. Role of Bim in regulating CD8+ T-cell responses during chronic viral infection. J. Virol. 80, 8627-8638 (2006).
56. Lopes, A.R. et al. Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. J. Clin. Invest. 118, 1835-1845 (2008).
57. Larrubia, J.R. et al. Persistent hepatitis C virus (HCV) infection impairs HCV-specific cytotoxic T cell reactivity through Mcl-1/Bim imbalance due to CD127 down-regulation. J. Viral Hepat. 20, 85-94 (2013).
58. Fisicaro, P. et al. Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV. Gastroenterology 143, 1576-1585e.4 (2012).
59. Nakamoto, N. et al. Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology 134, 1927-1937, 1937.e1-2 (2008).
60. Manigold, T. et al. Foxp3+CD4+CD25+ T cells control virus-specific memory T cells in chimpanzees that recovered from hepatitis C. Blood 107, 4424-4432 (2006).
61. Peppa, D. et al. Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathog. 6, e1001227 (2010).
62. Dolganiuc, A. et al. Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-a and plasmacytoid dendritic cell loss in chronic HCV infection. J. Immunol. 177, 6758-6768 (2006).
63. Tu, Z. et al. TLR-dependent cross talk between human Kupffer cells and NK cells. J. Exp. Med. 205, 233-244 (2008).
64. Duramad, O. et al. IL-10 regulates plasmacytoid dendritic cell response to CpG-containing immunostimulatory sequences. Blood 102, 4487-4492 (2003).
65. Groux, H., Bigler, M., de Vries, J.E. & Roncarolo, M.G. Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. J. Immunol. 160, 3188-3193 (1998).
66. Losikoff, P.T., Self, A.A. & Gregory, S.H. Dendritic cells, regulatory T cells and the pathogenesis of chronic hepatitis C. Virulence 3, 610-620 (2012).
67. Cox, A.L. et al. Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology 42, 104-112 (2005).
68. Callendret, B. et al. Transmission of clonal hepatitis C virus genomes reveals the dominant but transitory role of CD8+ T cells in early viral evolution. J. Virol. 85, 11833-11845 (2011).
69. Aubert, R.D. et al. Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection. Proc. Natl. Acad. Sci. USA 108, 21182-21187 (2011).
70. Han, S., Asoyan, A., Rabenstein, H., Nakano, N. & Obst, R. Role of antigen persistence and dose for CD4+ T-cell exhaustion and recovery. Proc. Natl. Acad. Sci. USA 107, 20453-20458 (2010).
71. Fuller, M.J. et al. Selection-driven immune escape is not a significant factor in the failure of CD4 T cell responses in persistent hepatitis C virus infection. Hepatology 51, 378-387 (2010).
72. Norris, S. et al. Resident human hepatic lymphocytes are phenotypically different from circulating lymphocytes. J. Hepatol. 28, 84-90 (1998).
73. Bonorino, P. et al. Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C. J. Hepatol. 51, 458-467 (2009).
74. Oliviero, B. et al. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 137, 1151-1160, 1160.e1-7 (2009).
75. Morishima, C. et al. Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing. Hepatology 43, 573-580 (2006).
76. Grégoire, C. et al. The trafficking of natural killer cells. Immunol. Rev. 220, 169-182 (2007).
77. Paust, S. et al. Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. Nat. Immunol. 11, 1127-1135 (2010).
78. O'Leary, J.G., Goodarzi, M., Drayton, D.L. & von Andrian, U.H. T cell-and B cell-independent adaptive immunity mediated by natural killer cells. Nat. Immunol. 7, 507-516 (2006).
79. Nattermann, J. et al. Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C. Gut 55, 869-877 (2006).
80. Varchetta, S. et al. Impaired intrahepatic natural killer cell cytotoxic function in chronic hepatitis C virus infection. Hepatology 56, 841-849 (2012).
81. Ahlenstiel, G. et al. Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-a-dependent manner. Gastroenterology 138, 325-335.e1-2 (2010).
82. De Maria, A. et al. Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients. Eur. J. Immunol. 37, 445-455 (2007).
83. Tjwa, E.T., van Oord, G.W., Hegmans, J.P., Janssen, H.L. & Woltman, A.M. Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B. J. Hepatol. 54, 209-218 (2011).
84. Takahashi, K. et al. Plasmacytoid dendritic cells sense hepatitis C virus-infected cells, produce interferon, and inhibit infection. Proc. Natl. Acad. Sci. USA 107, 7431-7436 (2010).
85. Lau, D.T. et al. innate immune tolerance and the role of Kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection. Gastroenterology 144, 402-413.e12 (2012).
86. Nguyen, K.B. et al. Interferon a/ß-mediated inhibition and promotion of interferon gamma: STAT1 resolves a paradox. Nat. Immunol. 1, 70-76 (2000).
87. Miyagi, T. et al. High basal STAT4 balanced by STAT1 induction to control type 1 interferon effects in natural killer cells. J. Exp. Med. 204, 2383-2396 (2007).
88. Edlich, B. et al. Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients. Hepatology 55, 39-48 (2012).
89. Miyagi, T. et al. Altered interferon-a-signaling in natural killer cells from patients with chronic hepatitis C virus infection. J. Hepatol. 53, 424-430 (2010).
90. Ahlenstiel, G. et al. Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology 141, 1231-1239, 1239.e1-2 (2011).
91. Bozzano, F. et al. Activating NK cell receptor expression/function (NKp30, NKp46, DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment. Eur. J. Immunol. 41, 2905-2914 (2011).
92. Oliviero, B. et al. Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection. J. Hepatol. published online, http://dx.doi.org/10.1016/j.jhep.2013.03.003 (14 March 2013).
93. He, X.S. et al. Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race. Hepatology 44, 352-359 (2006).
94. McGilvray, I. et al. Hepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotype. Gastroenterology 142, 1122-1131.e1 (2012).
95. Sarasin-Filipowicz, M. et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc. Natl. Acad. Sci. USA 105, 7034-7039 (2008).
96. Ge, D. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399-401 (2009).
97. Tanaka, Y. et al. Genome-wide association of IL28B with response to pegylated interferon-a and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41, 1105-1109 (2009).
98. Suppiah, V. et al. IL28B is associated with response to chronic hepatitis C interferon-a and ribavirin therapy. Nat. Genet. 41, 1100-1104 (2009).
99. Prokunina-Olsson, L. et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat. Genet. 45, 164-171 (2013).
100. Golden-Mason, L. et al. Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C. Hepatology 54, 1559-1569 (2011).
101. Ando, K. et al. Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J. Exp. Med. 178, 1541-1554 (1993).
102. Cavanaugh, V.J., Guidotti, L.G. & Chisari, F.V. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J. Virol. 71, 3236-3243 (1997).
103. Heise, T., Guidotti, L.G., Cavanaugh, V.J. & Chisari, F.V. Hepatitis B virus RNA-binding proteins associated with cytokine-induced clearance of viral RNA from the liver of transgenic mice. J. Virol. 73, 474-481 (1999).
104. Heise, T., Guidotti, L.G. & Chisari, F.V. Characterization of nuclear RNases that cleave hepatitis B virus RNA near the La protein binding site. J. Virol. 75, 6874-6883 (2001).
105. Jo, J. et al. Analysis of CD8+ T-cell-mediated inhibition of hepatitis C virus replication using a novel immunological model. Gastroenterology 136, 1391-1401 (2009).
106. Guidotti, L.G. et al. Viral clearance without destruction of infected cells during acute HBV infection. Science 284, 825-829 (1999).
107. Shin, E.C. et al. Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. J. Clin. Invest. 116, 3006-3014 (2006).
108. Webster, G.J. et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 32, 1117-1124 (2000).
109. Thimme, R. et al. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med. 194, 1395-1406 (2001).
110. Shoukry, N.H., Sidney, J., Sette, A. & Walker, C.M. Conserved hierarchy of helper T cell responses in a chimpanzee during primary and secondary hepatitis C virus infections. J. Immunol. 172, 483-492 (2004).
111. Fisicaro, P. et al. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 58, 974-982 (2009).
112. Dunn, C. et al. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 137, 1289-1300 (2009).
113. Yoon, J.C., Shiina, M., Ahlenstiel, G. & Rehermann, B. Natural killer cell function is intact after direct exposure to infectious hepatitis C virions. Hepatology 49, 12-21 (2009).
114. Crotta, S., Brazzoli, M., Piccioli, D., Valiante, N.M. & Wack, A. Hepatitis C virions subvert natural killer cell activation to generate a cytokine environment permissive for infection. J. Hepatol. 52, 183-190 (2010).
115. Sène, D. et al. Hepatitis C virus (HCV) evades NKG2D-dependent NK cell responses through NS5A-mediated imbalance of inflammatory cytokines. PLoS Pathog. 6, e1001184 (2010).
116. Yoon, J.C., Lim, J.B., Park, J.H. & Lee, J.M. Cell-to-cell contact with hepatitis C virus-infected cells reduces functional capacity of natural killer cells. J. Virol. 85, 12557-12569 (2011).
117. Bukowski, J.F., Woda, B.A., Habu, S., Okumura, K. & Welsh, R.M. Natural killer cell depletion enhances virus synthesis and virus-induced hepatitis in vivo. J. Immunol. 131, 1531-1538 (1983).
118. Welsh, R.M. & Waggoner, S.N. NK cells controlling virus-specific T cells: rheostats for acute vs. persistent infections. Virology 435, 37-45 (2013).
119. Waggoner, S.N., Cornberg, M., Selin, L.K. & Welsh, R.M. Natural killer cells act as rheostats modulating antiviral T cells. Nature 481, 394-398 (2012).
120. Waggoner, S.N., Taniguchi, R.T., Mathew, P.A., Kumar, V. & Welsh, R.M. Absence of mouse 2B4 promotes NK cell-mediated killing of activated CD8+ T cells, leading to prolonged viral persistence and altered pathogenesis. J. Clin. Invest. 120, 1925-1938 (2010).
121. Cook, K.D. & Whitmire, J.K. The depletion of NK cells prevents T cell exhaustion to efficiently control disseminating virus infection. J. Immunol. 190, 641-649 (2013).
122. Lang, P.A. et al. Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity. Proc. Natl. Acad. Sci. USA 109, 1210-1215 (2012).
123. Rabinovich, B.A. et al. Activated, but not resting, T cells can be recognized and killed by syngeneic NK cells. J. Immunol. 170, 3572-3576 (2003).
124. Peppa, D. et al. Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. J. Exp. Med. 210, 99-114 (2013).
125. Raué, H.P., Beadling, C., Haun, J. & Slifka, M.K. Cytokine-mediated programmed proliferation of virus-specific CD8+ memory T cells. Immunity 38, 131-139 (2013).
126. Friedman, S.L. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol. Rev. 88, 125-172 (2008).
127. Winau, F., Quack, C., Darmoise, A. & Kaufmann, S.H. Starring stellate cells in liver immunology. Curr. Opin. Immunol. 20, 68-74 (2008).
128. Radaeva, S. et al. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 130, 435-452 (2006).
129. Melhem, A. et al. Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J. Hepatol. 45, 60-71 (2006).
130. Taimr, P. et al. Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology 37, 87-95 (2003).
131. Glässner, A. et al. NK cells from HCV-infected patients effectively induce apoptosis of activated primary human hepatic stellate cells in a TRAIL-, FasL-and NKG2D-dependent manner. Lab. Invest. 92, 967-977 (2012).
132. Krämer, B. et al. NKp46high expression defines a NK cell subset that is potentially involved in control of HCV replication and modulation of liver fibrosis. Hepatology 56, 1201-1213 (2012).
133. Gur, C. et al. NKp46-mediated killing of human and mouse hepatic stellate cells attenuates liver fibrosis. Gut 61, 885-893 (2012).
134. Heise, T., Guidotti, L.G. & Chisari, F.V. La autoantigen specifically recognizes a predicted stem-loop in hepatitis B virus RNA. J. Virol. 73, 5767-5776 (1999).
135. Iannacone, M. et al. Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat. Med. 11, 1167-1169 (2005).
136. Kakimi, K. et al. Blocking chemokine responsive to 2/interferon (IFN)-inducible protein and monokine induced by IFN-activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. J. Exp. Med. 194, 1755-1766 (2001).
137. Sitia, G. et al. MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. J. Clin. Invest. 113, 1158-1167 (2004).
138. Sitia, G. et al. Depletion of neutrophils blocks the recruitment of antigen-nonspecific cells into the liver without affecting the antiviral activity of hepatitis B virus-specific cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA 99, 13717-13722 (2002).
139. Nakamoto, Y., Guidotti, L.G., Kuhlen, C.V., Fowler, P. & Chisari, F.V. Immune pathogenesis of hepatocellular carcinoma. J. Exp. Med. 188, 341-350 (1998).
140. Liaw, Y.F. & Chu, C.M. Hepatitis B virus infection. Lancet 373, 582-592 (2009).
141. Kwon, H. & Lok, A.S. Hepatitis B therapy. Nat. Rev. Gastroenterol. Hepatol. 8, 275-284 (2011).
142. Dabbouseh, N.M. & Jensen, D.M. Future therapies for chronic hepatitis C. Nat. Rev. Gastroenterol. Hepatol. 10, 268-276 (2013).
143. Zignego, A.L. & Brechot, C. Extrahepatic manifestations of HCV infection: facts and controversies. J. Hepatol. 31, 369-376 (1999).
144. Milich, D.R. et al. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc. Natl. Acad. Sci. USA 87, 6599-6603 (1990).
145. Chen, M. et al. Immune tolerance split between hepatitis B virus precore and core proteins. J. Virol. 79, 3016-3027 (2005).
146. Publicover, J. et al. IL-21 is pivotal in determining age-dependent effectiveness of immune responses in a mouse model of human hepatitis B. J. Clin. Invest. 121, 1154-1162 (2011).
147. Kaplan, D.E. et al. Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology 132, 654-666 (2007).
148. Urbani, S. et al. Acute phase HBV-specific T cell responses associated with HBV persistence after HBV/HCV coinfection. Hepatology 41, 826-831 (2005).
149. Chang, K.M. et al. Differential CD4+ and CD8+ T-cell responsiveness in hepatitis C virus infection. Hepatology 33, 267-276 (2001).
150. Urbani, S. et al. Virus-specific CD8+ lymphocytes share the same effector-memory phenotype but exhibit functional differences in acute hepatitis B and C. J. Virol. 76, 12423-12434 (2002).
151. Asabe, S. et al. The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J. Virol. 83, 9652-9662 (2009).
152. Stacey, A.R. et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J. Virol. 83, 3719-3733 (2009).
153. Wieland, S., Thimme, R., Purcell, R.H. & Chisari, F.V. Genomic analysis of the host response to hepatitis B virus infection. Proc. Natl. Acad. Sci. USA 101, 6669-6674 (2004).
154. Zeissig, S. et al. Hepatitis B virus-induced lipid alterations contribute to natural killer T cell-dependent protective immunity. Nat. Med. 18, 1060-1068 (2012).
155. Thomas, D.L. et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461, 798-801 (2009).
156. Shin, E.C. et al. Delayed induction, not impaired recruitment, of specific CD8+ T cells causes the late onset of acute hepatitis C. Gastroenterology 141, 686-695, 695.e1 (2011).
157. Maini, M.K. et al. The role of virus-specific CD8+ cells in liver damage and viral control during persistent hepatitis B virus infection. J. Exp. Med. 191, 1269-1280 (2000).
158. Shetty, S., Lalor, P.F. & Adams, D.H. Lymphocyte recruitment to the liver: molecular insights into the pathogenesis of liver injury and hepatitis. Toxicology 254, 136-146 (2008).
159. Shields, P.L. et al. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J. Immunol. 163, 6236-6243 (1999).
160. Tan, A.T. et al. A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B. J. Hepatol. 52, 330-339 (2010).
161. Rossol, S. et al. Interleukin-12 induction of TH1 cytokines is important for viral clearance in chronic hepatitis B. J. Clin. Invest. 99, 3025-3033 (1997).
162. Webster, G.J. et al. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J. Virol. 78, 5707-5719 (2004).
163. Zeremski, M. et al. Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection. J. Infect. Dis. 200, 1774-1780 (2009).
164. Zeremski, M. et al. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology 48, 1440-1450 (2008).
165. Casrouge, A. et al. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J. Clin. Invest. 121, 308-317 (2011).